Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.

Abstract

BACKGROUND:

Cutaneous melanoma is the most serious skin malignancy and new therapeutic strategies are needed for advanced melanoma. TP53 mutations are rare in cutaneous melanoma and hence activation of wild-type p53 is a potential therapeutic strategy in cutaneous melanoma. Here, we investigated the WIP1 inhibitor, GSK2830371, and MDM2-p53 binding antagonists (nutlin-3, RG7388 and HDM201) alone and in combination treatment in cutaneous melanoma cell lines and explored the mechanistic basis of these responses in relation to the genotype and induced gene expression profile of the cells.

METHODS:

A panel of three p53WT (A375, WM35 and C8161) and three p53MUT (WM164, WM35-R and CHL-1) melanoma cell lines were used. The effects of MDM2 and WIP1 inhibition were evaluated by growth inhibition and clonogenic assays, immunoblotting, qRT-PCR gene expression profiling and flow cytometry.

RESULTS:

GSK2830371, at doses (⩽10 μM) that alone had no growth-inhibitory or cytotoxic effects on the cells, nevertheless significantly potentiated the growth-inhibitory and clonogenic cell killing effects of MDM2 inhibitors in p53WT but not p53MUT melanoma cells, indicating the potentiation worked in a p53-dependent manner. The siRNA-mediated knockdown of p53 provided further evidence to support the p53 dependence. GSK2830371 increased p53 stabilisation through Ser15 phosphorylation and consequent Lys382 acetylation, and decreased ubiquitination and proteasome-dependent degradation when it was combined with MDM2 inhibitors. These changes were at least partly ATM mediated, shown by reversal with the ATM inhibitor (KU55933). GSK2830371 enhanced the induction of p53 transcriptional target genes, cell cycle arrest and apoptosis.

CONCLUSIONS:

GSK2830371, a WIP1 inhibitor, at doses with no growth-inhibitory activity alone, potentiated the growth-inhibitory and cytotoxic activity of MDM2 inhibitors by increasing phosphorylation, acetylation and stabilisation of p53 in cutaneous melanoma cells in a functional p53-dependent manner.

• Authors: Chiao-En Wu, Arman Esfandiari, Yi-Hsuan Ho, Nan Wang, Ahmed Khairallah Mahdi, Erhan Aptullahoglu, Penny Lovat, John Lunec
• Journal: British journal of cancer (Br J Cancer) Vol. 118 Issue 4 Pg. 495-508 (02 20 2018) ISSN: 1532-1827 [Electronic] England
• PMID: 29235570 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Aminopyridines
• Dipeptides
• GSK2830371
• Imidazoles
• Piperazines
• Pyrrolidines
• RG7388
• TP53 protein, human
• Tumor Suppressor Protein p53
• para-Aminobenzoates
• nutlin 3
• MDM2 protein, human
• Proto-Oncogene Proteins c-mdm2
• PPM1D protein, human
• Protein Phosphatase 2C

Topics

• Aminopyridines (pharmacology)
• Cell Cycle (drug effects)
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Cell Survival (drug effects)
• Dipeptides (pharmacology)
• Drug Synergism
• Gene Expression Profiling
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Imidazoles (pharmacology)
• Melanoma (drug therapy, genetics, metabolism)
• Mutagenesis, Site-Directed
• Phosphorylation
• Piperazines (pharmacology)
• Protein Binding (drug effects)
• Protein Phosphatase 2C (antagonists & inhibitors)
• Protein Stability
• Proto-Oncogene Proteins c-mdm2 (antagonists & inhibitors)
• Pyrrolidines (pharmacology)
• Skin Neoplasms (drug therapy, genetics, metabolism)
• Tumor Suppressor Protein p53 (chemistry, genetics, metabolism)
• para-Aminobenzoates (pharmacology)
• Melanoma, Cutaneous Malignant